This site is intended for healthcare professionals

CAPTIVATE study shows an Imbruvica + Venclexta combination has potential for remission in CLL/SLL patients.- AbbVie

Read time: 1 mins
Last updated:9th Jun 2021
Published:10th Jun 2021
AbbVie announced new data from the Phase II CAPTIVATE (PCYC-1142) study investigating Imbruvica (ibrutinib) in combination with Venclexta (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) during an oral presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7501).
Condition: CLL/SLL
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest